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OBJECTIVE — Abnormal small nerve ﬁber function may be an early feature of diabetic
neuropathy and may also underlie painful symptoms. Methods for assessing small-ﬁber damage
include quantitative sensory testing (QST) and determining intraepidermal nerve ﬁber density.
We recently described a reproducible physiological technique, the LDIﬂare, which assesses
small-ﬁber function and thus may reﬂect early dysfunction before structural damage. The value
ofthistechniqueinpainfulneuropathywasassessedbycomparingitwithQSTanddermalnerve
ﬁber density (NFD).
RESEARCH DESIGN AND METHODS — Fifteen healthy control subjects, 10 subjects
with type 2 diabetes and painful neuropathy (PFN), and 12 subjects with type 2 diabetes and
painless neuropathy (PLN) were studied. LDIﬂare and QST were performed on the dorsum of
the foot, and dermal NFD was determined.
RESULTS — Resultsofbothlarge-andsmall-ﬁberquantitativesensorytestswereabnormalin
patientswithPLNbutnotthosewithPFNcomparedwithcontrolsubjects.DermalNFDwasalso
signiﬁcantly reduced in the PLN group compared with control subjects (205.8  165.3 vs.
424.9176.3[meanSD];P0.003)butnotinthePFNgroup(307.6164.5).Incontrast,
theLDIﬂare(squarecentimeters)wasreducedinbothPFN(1.590.41)andPLN(1.510.56)
groups compared with control subjects (4.38  1.4) (P  0.001 for both). NFD correlated
signiﬁcantly with the LDIﬂare (r  0.57, P  0.0001).
CONCLUSIONS — The LDIﬂare demonstrated impaired small-ﬁber function in patients
with PFN when other assessments revealed no abnormality. We believe that this method has
potential diagnostic value, particularly because it is noninvasive, has excellent reproducibility,
and correlates with NFD. Furthermore, it may have an important role in assessing preventative
therapies in early neuropathy.
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eripheral neuropathy affects between
40 and 60% of individuals with di-
abetes and is commonly diagnosed
by assessing large-ﬁber sensory modali-
ties. However, detection of small-ﬁber
neuropathy may be of equal or more im-
portance for several reasons. Structural
and functional changes in small ﬁbers
precede large-ﬁber pathological changes
and have been implicated in foot ulcer-
ation and delayed wound healing (1–3).
Furthermore, C-ﬁber dysfunction may be
involved in the genesis of neuropathic
pain (4).
Until recently, few objective methods
have been available to quantify small-
ﬁber function. Quantitative sensory tests
to deﬁne thermal and pain thresholds
using the Computer Aided Sensory Eva-
luator–IV (CASE IV; WR Medical Elec-
tronics, Stillwater, MN) or the TSA-II
NeuroSensory Analyzer (Medoc Ad-
vanced Medical Systems, Ramat Ysihai,
Israel) have been used primarily in clini-
cal research (5,6). However, they are de-
pendent on subjective responses and
therefore have a high interobserver vari-
abilityandpoorreproducibility(7,8).We
recently described a novel and reproduc-
ible (coefﬁcient of variation 15%) tech-
nique to assess small-ﬁber dysfunction,
the “LDIﬂare,” which measures axon re-
ﬂex–mediated vasodilatation in response
to skin heating (9). We have also demon-
strated that LDIﬂare detects early C-ﬁber
dysfunction in type 2 diabetes before
small-ﬁberneuropathycanbedetectedby
other currently available noninvasive
methods (10). However, the structural
basis for an abnormal LDIﬂare response
has not been established.
Although intraepidermal nerve ﬁber
density(IENFD),withgoodintraobserver
reproducibility, has been increasingly
used to diagnose small-ﬁber neuropa-
thies, it is an invasive procedure (11,12).
In the present study we assessed small-
ﬁber function using quantitative sensory
testing (QST) and the LDIﬂare and com-
paredtheseresultswiththeresultsofder-
mal NFD in foot skin biopsy specimens
from the same area. Dermal NFD as op-
posed to IENFD was quantiﬁed to deﬁne
theunderlyingstructuralbasisoftheLDI-
ﬂare,asthisdependsonanabnormalityin
dermalbloodﬂow.Inaddition,asthereis
no current consensus as to whether an
abnormality in small-ﬁber dysfunction
and damage underlie painful diabetic
neuropathy, we compared diabetic pa-
tients with painful neuropathy (PFN) and
painless neuropathy (PLN).
RESEARCH DESIGN AND
METHODS— Type 2 diabetic pa-
tients with PFN (n  10) and PLN (n 
12) and 15 healthy control subjects were
studied. Patients with diabetes were re-
cruited from the outpatient clinics of
the Ipswich Hospital Diabetes Centre
(Ipswich, U.K.). Subjects with absent
pedal pulses or evidence of peripheral
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subjects had an ankle brachial pressure
index (ABPI) of 0.8. The study was ap-
provedbythelocalethicscommittee,and
all the subjects gave informed written
consent.
Assessment of LDIﬂare
Subjects were allowed to acclimatize for
30 min in a temperature-controlled room
in which the temperature was maintained
at 25  1°C. The foot temperature was
measuredproximaltotheﬁrstandsecond
metatarsal heads using an infrared ther-
mometer (Linear Laboratories, Fremont,
CA). The axon reﬂex–mediated LDIﬂare
was examined using a laser Doppler im-
ager (LDI) (Moor Instruments, Devon
U.K.) and our established methodology
(10). Skin proximal to the ﬁrst and sec-
ond metatarsal heads on the dorsum was
heated with a circular skin heater (diam-
eter 1.0 cm; Moor Instruments) to 44°C
for 20 min. An area of 3.5  3.5 cm sur-
rounding the heated skin was scanned
with the LDI immediately after careful re-
moval of the heater probe. We have
shown previously that removal of the
heater along with the holder does not
have an impact on the size of the ﬂare
(10). On the ﬂux image, the region of in-
terest demarcated by the edge of the ﬂare
was drawn, and the area of the LDIﬂare
was calculated using Moor LDI software
(version 3.11) and expressed in square
centimeters.
Clinical neuropathy assessment
Vibrationperceptionthreshold(VPT)was
assessed using the Neurothesiometer
(Horwell Scientiﬁc Laboratory Supplies,
Nottingham,U.K.)atthepulpofthegreat
toe using the ascending method of limits.
The results were expressed in volts, and a
value of 51 was assigned if the subjects
could not feel the maximum vibration.
TherightfootwasassessedusingtheNeu-
ropen (Owen Mumford, Oxford, U.K.),
which contains a 10-g monoﬁlament to
assesspressureperceptionandaNeurotip
(Owen Mumford) for pinprick sensation
(13,14). Ten-gram monoﬁlaments were
appliedfor2sontheplantaraspectofthe
ﬁrst,third,andﬁfthmetatarsalheads,and
the Neurotip was applied at the eponych-
ium of the ﬁrst toe. Subjects with an ab-
normal response using the Neuropen
assessment and/or impaired VPT (15 V,
i.e., 95th percentile for this age-group)
were classiﬁed as having neuropathy.
Subjects with typical painful neuropathic
symptomswithavisualanalogscalescore
4 for 6 months were classiﬁed as hav-
ing PFN (15). Quantitative sensory tests
using the CASE IV, including vibration
detectionthreshold(VDT),colddetection
threshold (CDT), warmth detection
threshold (WDT), and heat pain onset
(HPO) were performed with software
CASE IV (version 4.27.1; WR Medical
Electronics). VDT, CDT, and WDT were
measured using the 4, 2, 1 stepping algo-
rithm with null stimuli (5). The VDT was
obtained on the dorsal aspect of the hal-
lux, and CDT and WDT were examined
on the dorsum of the midfoot. For each
test, the computer calculated the “just
noticeable difference” (JND) from the
subject’s responses, with a higher JND re-
ﬂecting a larger amplitude of the stimulus
(vibration) or larger change in tempera-
ture (thermal). A value of 26 was given if
theJNDwasgreaterthanthemaximumof
25.
Skin biopsy
Onadifferentday,skinbiopsieswereper-
formed using a sterile 3-mm biopsy
punch (Stiefel Laboratories, Bucks, U.K.)
in the same area where the LDIﬂare had
been assessed previously. All subjects tol-
erated the biopsy, and there was no infec-
tion or other adverse event.
Fixation immunostaining protocol
Thebiopsyspecimenwasimmersedin5
ml of 4% buffered paraformaldehyde
for 18–24 h, washed with Tris-buffered
saline (TBS) buffer for 15 min, and
transported to the laboratory to be em-
bedded in parafﬁn wax. Wax blocks
were cut on the microtome into thin
sections (5 m), which were mounted
on positively charged slides (three per
slide),dewaxedinxylene,andgradually
rehydrated through decreasing ethanol
dilutions. In all cases, epidermal mela-
nin was bleached with 0.25% KMnO4
and 5% oxalate before serum protein
block. Before applying primary anti-
body, an enzymatic antigen retrieval
pretreatment with trypsin was used for
anti-CD31 and anti-CD34 for blood
vessels. Tissue was washed with Tween
20 detergent/TBS buffer before the run
was started; 3% hydrogen peroxide was
used to block endogenous peroxidase
and a TBS-buffered solution of 1:10
normal serum was used for protein
block. Dilution of anti-protein gene
product (PGP) 9.5 rabbit anti-human
polyclonal antibody was 1:100, and it
was applied for 60–72 h at 5°C. CD34
(dilution 1:300) and CD31 (dilution
1:50) polyclonal mouse antihuman
antibodies were applied overnight at
5°C. After addition of secondary anti-
body (swine anti-rabbit for PGP), a
streptavidin-horseradish–conjugated
peroxidaseand3,3-diaminobenzidine
chromogen substrate were used to de-
tect binding of the primary antibodies.
Negative controls comprised sections
that underwent the same runs except
that the primary antibody was omitted.
Developing time was exactly the same
for all sections in each separate run, and
in each run the sections were processed
synchronously.
Image analysis
Patterns of immunostaining were exam-
ined by light microscopy (Leitz DM RB
microscope). Digital images were cap-
tured at 400 magniﬁcation with a Ni-
kon digital camera and analyzed with
Leica QWin Standard V2.4 (Leica Micro-
system Imaging, Cambridge, U.K.) set to
detect color intensities in a ﬁxed and con-
stant range. Every image was evaluated
using a standardized Leica program to
quantify the amount of stained and total
areas (Leica QWin Standard V2.4). The
PGP 9.5 positively stained proﬁles and
blood vessel cross-sections were counted
manually and divided by the dermal area
to obtain a density (number per square
millimeter). Because PGP 9.5 ubiqui-
tously stains all nerve ﬁbers, both sensory
and autonomic C ﬁbers in the dermis
wereincluded.Thebloodvesselscounted
were predominantly capillaries, although
some precapillary arterioles or postcapil-
lary venules may have been included as
cross-sections were studied. Large arte-
rioles and venules were not counted. All
observations were performed on coded
slides to prevent observer bias.
Statistical analysis
Descriptive statistics were used to de-
scribe subject characteristics. Nonpara-
metric analysis (Kruskal-Wallis test and
Mann-Whitney U test) was used to deter-
mine differences between the groups.
Pearson’s correlation coefﬁcient was used
to correlate the variables. The results are
expressed as means  SD. P  0.05 was
considered to be signiﬁcant. SPSS (ver-
sion11.0,SPSS,Chicago,IL)wasusedfor
the statistical analysis.
RESULTS— Clinical characteristics of
the subjects with diabetes and control
subjectsareshowninTable1.Allsubjects
were Caucasian and were matched for
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beticgroupswassimilar.Asexpected,the
BMI was lower in the control group but
was similar in the two diabetic groups.
A1C was not signiﬁcantly different in the
two diabetic groups. ABPIs were similar
in all three groups.
The neurological assessments are
shown in Table 2. VPT, VDT, WDT,
CDT, and HPO were signiﬁcantly higher
in the PLN group but not in the PFN
group compared with healthy control
subjects (Table 2). However, the LDIﬂare
was signiﬁcantly reduced in both diabetic
groups compared with the healthy con-
trol subjects (healthy control subjects
4.38  1.4 cm
2, PLN group 1.59  0.41
cm
2, and PFN group 1.51  0.56 cm
2;
P  0.0001). In contrast, the NFD was
signiﬁcantly reduced in the PLN group
compared with that in healthy control
subjects (205.8  165.3 vs. 424  176.3
mm
2; P  0.003) but not in the PFN
group (307.6  164.5 vs. 424  176.3
mm
2; P  0.13). There was no signiﬁcant
difference between the PFN and PLN
groups for either LDIﬂare or NFD (LDI-
ﬂare: PLN 1.59  0.41 cm
3 vs. PFN
1.51  0.56 cm
3; P  0.49; NFD: PLN
205.8  165.3 mm
2 vs. PFN 307.6 
164.5 mm
2; P  0.12). There was also no
signiﬁcant difference in dermal vascular
density among any groups (Table 2). The
LDIﬂare correlated signiﬁcantly with der-
mal NFD (Fig. 1) (r  0.57; P  0.0001)
in all subjects combined and also within
control subjects (r  0.53; P  0.05) and
inthePFNgroup(r0.71;P0.05)but
not in the PLN group (r  0.38, P 
0.22).
CONCLUSIONS— Asigniﬁcantnum-
ber of patients with diabetic neuropathy
present with pain as their ﬁrst neuro-
pathic symptom. Many of these patients
have no objective clinical signs. It has
been suggested that this is because con-
ventional bedside tests such as reﬂexes,
pressuresensation,andvibrationrelateto
large-ﬁber function, whereas pain sensa-
tion conveyed by small unmyelinated C-
ﬁbers and A- ﬁbers is not revealed by
these tests (15). In this study we com-
pared the ability to deﬁne an underlying
abnormality in small-ﬁber dysfunction,
usingthenoveltechniqueofLDIﬂarewith
established QST using CASE IV and der-
mal skin NFD in patients with diabetic
neuropathy.
In diabetic patients with PLN, as ex-
pected, results of all neurological tests in-
cludingVPT,QST,andLDIﬂareandNFD
wereabnormal,consistentwiththeexten-
sive nerve damage in this group (10).
However, in patients with PFN, there was
no bedside evidence of neuropathy;
i.e., they had intact reﬂexes and 10-g
monoﬁlament sensation. Furthermore,
large-ﬁber(VPTandVDT)and,moresur-
prisingly, small-ﬁber function (WDT,
CDT, and HPO) assessed by QST did not
differ signiﬁcantly from those in the con-
trol subjects.
In contrast, in the PFN group, the
LDIﬂarewastheonlytestthatshowedab-
normal results, and, indeed, this showed
impairment as severe as that in the PLN
group. The NFD in the PFN group, al-
thoughlower,wasnotsigniﬁcantlydiffer-
ent from that of the control subjects and
laybetweenthatofpatientswithPLNand
the control group.
A reduced LDIﬂare response may oc-
cur because of impaired C-ﬁber function,
loss of C-ﬁbers, reduced microvascular
vasodilatation (including in response to
vasoactive peptides), or reduced blood
vessel density. The latter is unlikely, as
there was no signiﬁcant difference in the
dermal blood vessel density between the
three groups, and, indeed, in previous
studies we have found no reduction in
blood vessel density in individuals with
diabetes (9). Although it is widely recog-
nized that hyperemic responses are re-
duced in individuals with diabetes, this
reduction only relates to maximal hyper-
emia; we have previously shown that the
ﬂare response in terms of the area over
which the ﬂare spreads after skin heating
is clearly demonstrable even in subjects
with severely impaired maximal hyper-
emia (10). Thus, the smaller ﬂares are not
a result of either reduced blood vessel
density or reduced maximal vasodilata-
tion response. We speciﬁcally assessed
dermalNFDasopposedtoIENFD,asder-
mal NFD provides a direct measure of the
structural integrity of the innervation of
the dermal blood vessels and, hence, the
Table 1—Clinical characteristics of subjects
Healthy control
subjects
Type 2 diabetic subjects
PFN PLN
Sex (male/female) 5/10 5/5 6/6
Age (years) 54.4  9.7 61.0  11.2 62.9  10.2
Duration (years) — 12.1  4.2 13.3  4.29
BMI (kg/m
2) 25.4  2.4 30.7  3.1 32.3  2.8
A1C (%) — 8.2  3.8 8.6  3.5
ABPI 1.1  0.1 1.0  0.2 1.2  0.1
VPT 7.08  2.8 8.6  2.2 37.1  12.9
VAS (0–10) 0 5.7  1.1 0
Data are means  SD. There were no signiﬁcant differences in age between the healthy control, PFN, and
PLN groups. BMI was lower in the control subjects than in the PFN and PLN groups (P  0.001 and P 
0.0001, respectively). Duration of diabetes and A1C were not signiﬁcantly different between the PFN and
PLNgroups.ABPIwasnotdifferentamongthethreegroups.VPTwasnotsigniﬁcantlydifferentbetweenthe
healthy control and PFN groups but high in the PLN group (P  0.0001). Visual analog scale (VAS) was
high in the PFN group.
Table 2—Neurological assessments
Healthy control
subjects
Type 2 diabetic subjects
PFN PLN
LDIﬂare (cm
2) 4.38  1.4 1.59  0.4* 1.51  0.56*
Dermal nerve density (mm
2) 424  176.3 307.6  164.5 205.8  165.3†
Dermal vascular density (mm
2) 115.8  23.7 129.9  23.8 103.4  27.1
VPT (V) 7.0  2.8 8.7  2.2 37.0  12.9*
VDT (JND) 18.4  3.2 19.5  3.2 23.0  3.7‡
CDT (JND) 10.4  5.0 13.8  5.1 19.5  4.6*
WDT (JND) 17.5  2.0 18.3  6.1 25.2  1.8*
HPO (JND) 21.6  1.8 21.3  3.0 25.3  1.6*
Data are means  SD. Except for LDIﬂare, none of the neurovascular parameters were signiﬁcantly different
in the PFN group compared with the healthy control subjects. P values compared with healthy control
subjects: *P  0.0001; †P  0.003; ‡P  0.005.
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ence in dermal NFD between those with
PFN and control subjects; this ﬁnding
suggests that the reduced ﬂare reﬂects
functional as opposed to structural im-
pairmentintheaxonreﬂexpathway.This
observation further supports the para-
digm that impaired small-ﬁber function
occurs before the development of large-
ﬁber neuropathy, but, in addition, we
nowdemonstratethatthisprecedesstruc-
tural defects to the small ﬁbers.
Severalstudieshaveshownthatindi-
abetes the degree of intraepidermal nerve
ﬁber loss correlates with the severity of
the neuropathy (16–18). However, few
studies have focused speciﬁcally on der-
mal NFD in painful diabetic neuropathy.
Lauriaetal.(19)foundreducedIENFDin
a study of six patients with painful dia-
betic neuropathy compared with that in
normal control subjects. In another study
of patients with neuropathic pain, So-
rensen et al. (20) paradoxically found
more severe IENFD loss compared with
thatinthosewithPLN.Fromthisﬁnding,
theyconcludedthatlossofIENFDcannot
explaingenesisofpaininallpatients.Los-
eth et al. (21) also reported signiﬁcantly
lower IENFD and higher cold perception
thresholds in patients with diabetes and
normalnerveconductionstudieswhether
they had painful symptoms or not.
There are several reasons why we did
not ﬁnd a signiﬁcant difference in nerve
ﬁber density in comparison with the
above studies. Patient selection may be
important, as our patients had no clinical
signs of neuropathy and may thus repre-
sent an earlier phase in the pathological
process. The majority of studies have ex-
amined IENFD as opposed to dermal
NFD. From previous reports it would ap-
pear that IENFD may be a more useful
diagnostic test for detecting early struc-
tural nerve damage, as intraepidermal
nervesaremoredistalthandermalnerves.
However, the assessment of dermal NFD
may provide more mechanistic insights
into the pathogenesis of painful diabetic
neuropathy, as it provides a measure of
dermal blood vessel innervation and,
hence, any potential impact on dermal
blood ﬂow. Indeed, we have previously
demonstrated an impairment of cutane-
ous endothelium-related vasodilatation
andC-ﬁber–mediatedvasoconstrictionin
painful diabetic neuropathy and sug-
gestedthatinappropriatelocalbloodﬂow
regulation may have a role in the patho-
genesis of pain in diabetic neuropathy
(22). A recent study conﬁrms the valid-
ity of assessing alterations in dermal
NFD in thin sections and has speciﬁ-
cally demonstrated a reduction in arte-
riolarinnervationinpatientswithsmall-
ﬁberneuropathy(23).Furthermore,the
assessment of dermal NFD in addition
to IENFD has been shown to improve
the diagnostic sensitivity for detecting
painful sensory neuropathy (24). Fi-
nally, functional defects in unmyeli-
nated C-ﬁbers may precede structural
defects (25), which would be detected
by an abnormal LDIﬂare but with no
effect on NFD, as demonstrated in this
study. It is of importance that the LDI-
ﬂare results correlated with NFD in the
groups combined as well as separately
in the control and PFN groups. This re-
sult would be expected because the size
of the ﬂare response should relate not
only to neural function but also to the
actual number of functioning nerves. It
was not unexpected that there would be
no correlation between the ﬂare re-
sponse and NFD in the PLN group be-
cause whether or not dermal nerve
ﬁbers were identiﬁed, all modalities of
nerve function were severely impaired
or absent with little or no graduation in
this group.
In summary, using the LDIﬂare tech-
nique, we have demonstrated abnormal
C-ﬁber function in subjects with symp-
tomatic PFN in whom results of conven-
tional quantitative sensory tests were
normal and in whom there was no signif-
icant reduction in NFD. Because of the
small sample size in the current study,
furtherstudieswithlargernumbersofpa-
tients are required to conﬁrm these ﬁnd-
ings and to determine the sensitivity and
speciﬁcity of the LDIﬂare as a diagnostic
modality in painful diabetic neuropathy.
Because the LDIﬂare detects small-ﬁber
dysfunction before the occurrence of po-
tentially irreversible structural loss of
nerve ﬁbers, in addition to its potential
diagnostic value, it may have an impor-
tant role in assessing preventative thera-
pies in early neuropathy.
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Figure 1—Correlation of LDIﬂare and NFD. The LDIﬂare results correlated signiﬁcantly with
dermalNFD(r0.57;P0.0001)inallsubjectscombinedandwithincontrolsubjects(● )(r
0.53;P0.05)andinthePFNgroup(Œ)(r0.71;P0.05)butnotinthePLNgroup(f)(r
0.38; P  0.22).
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